Skip to main content

. 1977 Oct 15;2(6093):1001–1003. doi: 10.1136/bmj.2.6093.1001

Post-marketing surveillance of adverse reactions to new medicines.

PMCID: PMC1631773 PMID: 922357

1001

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Brown P., Baddeley H., Read A. E., Davies J. D., McGarry J. Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol). Lancet. 1974 Dec 21;2(7895):1477–1481. doi: 10.1016/s0140-6736(74)90218-9. [DOI] [PubMed] [Google Scholar]
Howie J. G. Drug monitoring and adverse reactions. Br Med J. 1977 Jun 4;1(6074):1467–1467. doi: 10.1136/bmj.1.6074.1467. [DOI] [PMC free article] [PubMed] [Google Scholar]
Jick H. The discovery of drug-induced illness. N Engl J Med. 1977 Mar 3;296(9):481–485. doi: 10.1056/NEJM197703032960904. [DOI] [PubMed] [Google Scholar]
Lawson D. H., Henry D. A. Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"? Br Med J. 1977 Mar 12;1(6062):691–692. doi: 10.1136/bmj.1.6062.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
Skegg D. C., Doll R., Perry J. Use of medicines in general practice. Br Med J. 1977 Jun 18;1(6076):1561–1563. doi: 10.1136/bmj.1.6076.1561. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES